Fawad Yousuf, MBBS

Personal Statement

Dr. Fawad Yousuf graduated from Allama Iqbal Medical College, Lahore, Pakistan. Before joining the University of Kentucky, he completed postdoctoral fellowship in neuroimaging in Multiple Sclerosis at Brigham and Women’s Hospital, Harvard Medical School. Dr. Yousuf's research includes the use of MRI to study mechanisms and predictors of disease progression in multiple sclerosis. He enjoys teaching and plans to combine academics with clinical practice in future. Dr. Yousuf's clinical and research interests include neuroimmunology, multiple sclerosis and neuromuscular.
Outside medicine Dr. Yousuf is a person who treasures his family and friends and loves spending time with them. In his leisure time, he likes to play cricket, listen to sufi music and read about the advancements in astrophysics.

Medical School

2007, MBBS, Allama Iqbal Medical College, Lahore, Pakistan

Postdoctoral Fellowship

Neuroimaging in Multiple sclerosis, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Residency

2017 to present, Neurology, University of Kentucky, Lexington, KY

Clinical and Research Interests

Neuroimmunology, Multiple Sclerosis and Neuromuscular 

Fellowship Plans

Multiple Sclerosis, Neuroimmunology.

Medical Licensure

Kentucky Medical License

Certifications

  • Advanced Cardiovascular Life Support Certification (ACLS)
  • Humanitarian Use Devices. Collaborative Institutional Training Initiative (CITI)
  • National Institutes of Health Stroke Scale Certification

Hospital Privileges

University of Kentucky Chandler Medical Center

Professional Memberships

  • American Academy of Neurology
  • American Society of Neuroimaging

Publications and Abstracts

RESEARCH & INTELLECTUAL CONTRIBUTIONS

Publications/Peer-Reviewed Original Research in Professional, Scientific or Educational Journals 

  • Yousuf F, Kim G, Tauhid S, Glanz BI, Chu R, Tummala S, Healy BC, Bakshi R. The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. Front Neurol. 2016; 7:99. PMID: 27445966; PMCID: PMC4925661.
  • Dupuy SL, Tauhid S, Hurwitz S, Chu R, Yousuf F, Bakshi R. The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis. Neurol Ther. 2016 Dec; 5(2):215-229. PMID: 27744504.
  • Kim G, Chu R, Yousuf F, Tauhid S, Stazzone L, Houtchens MK, Stankiewicz JM, Severson C, Kimbrough D, Quintana FJ, Chitnis T, Weiner HL, Healy BC, Bakshi R. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. Int J Neurosci. 2017 Feb 02; 1-10. PMID: 28100092.
  • Shinohara RT, Oh J, Nair G, Calabresi PA, Davatzikos C, Doshi J, Henry RG, Kim G, Linn KA, Papinutto N, Pelletier D, Pham DL, Reich DS, Rooney W, Roy S, Stern W, Tummala S, Yousuf F, Zhu A, Sicotte NL, Bakshi R. Volumetric analysis from a harmonized multisite brain MRI study of a single subject with Multiple Sclerosis. NAIMS Cooperative. AJNR Am J Neuroradiol. 2017 Aug;38(8):1501-1509. PMID: 286422663
  • Yousuf F, Dupuy S, Tauhid S, Chu R, Kim G, Tummala S, Khalid F, Wein-er H, Chitnis T, Healy B, Bakshi R. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. Journal of the Neurological Sciences. 2017; 383:221-229

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

  • Yousuf F, Tauhid S, Hurwitz S, Treaba CA, Ouellette R, Muelas EH, Willmer J, Mainero C, Bakshi R. Segmentation of the cerebral deep gray matter nuclei using 3T and 7T MRI in patients with multiple sclerosis (P4. 378). Neurology. 2017 Apr 18;88(16 Supplement):P4-378.
  • Yousuf F, Dupuy S, Tauhid S, Chu R, Kim G, Tummala S, Chitnis T, Healy BC, Bakshi R. The effect of fingolimod on cerebral gray matter atrophy in multiple sclerosis. In Multiple Sclerosis Journal 2016 Sep 1 (Vol. 22, pp. 549).
  •  Yousuf F, Kim G, Tauhid S, Glanz B, Chu R, Tummala S, Healy B, Bakshi R. The Contribution of Cortical Lesions to a Magnetic Resonance Disease Severity Scale in Multiple Sclerosis (P4. 168). Neurology. 2016 Apr 5;86(16 Supplement):P4-168.
  • Ouellette R, Treaba CA, Granberg T, Herranz E, Barletta V, De Leener B, Tauhid S, Yousuf F, Dupont S, Klawiter EC, Sloane JA, Bakshi R, Cohen-Abad J, Mainero C. (October, 2017). Characterization of spinal cord pathology and its correlates at ultra-high field MRI. Poster presented at: 33rd Congress of the European Committee For Treatment And Research In Multiple Sclerosis; Paris, France.
  •  Singhal T, O'Connor K, Dubey S, Belanger A, Chu R, Tauhid S, Dupuy S, Yousuf F, Kijewski M, DiCarli M, Weiner H. Assessing Cerebral Microglial Activation Using a Novel [F-18]-Based Positron Emission Tomography Ligand in Multiple Sclerosis. In Multiple Sclerosis Journal 2017 Feb 1 (Vol. 23, No. 1, pp. 92-93).
  • Ouellette R, Granberg T, Treaba CA, Herranz E, De Leener B, Sloane J, Tauhid S, Yousuf F, Dupont S, Klawiter E, Bakshi R. In vivo characterization of grey and white matter spinal cord pathology in multiple sclerosis using ultra high field MRI (P4. 365). Neurology. 2017 Apr 18;88(16 Supplement):P4-365.  
  • Dupuy S, Yousuf F, Tauhid S, Chu R, Kim G, Tummala S, Chitnis T, Healy B, Bakshi R. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis (P5. 354). Neurology. 2017 Apr 18;88(16 Supplement):P5-354.
  • Bakshi R, Dupuy S, Bucci M, Keshavan A, Khalid F, Kirkish G, Panara V, Tauhid S, Yousuf F, Zhu A, Weiner H. Comparing 5 year clinical-MRI relationships in two comprehensive care multiple sclerosis centers in the SUMMIT study (P5. 355). Neurology. 2017 Apr 18;88(16 Supplement):P5-355.
  • Shinohara R.T, Calabresi P.A, Davatzikos C, Doshi J, Henry R.G, Kim G, Linn K.A, Nair G, Oh J, Papinutto N, Pham D.L, Reich D.S, Rooney W, Roy S, Sicotte N.L, Stern W, Tummala S, Yousuf F, Zhu A, and Bakshi R. (September, 2016). Inter-scanner MRI variability of multiple sclerosis lesion and tissue volumes in the NAIMS cooperativePoster presened at: 32nd Congress of the European Committee For Treatment And Research In Multiple Sclerosis; London, GBR.
  • Tauhid S, Chu R, Kim G, Yousuf F, Healy B, Bakshi R. Sample Size Requirements for Treatment Effects Using Deep Gray Matter Volume from 3T MRI in Progressive Forms of Multiple Sclerosis (P4. 173). Neurology. 2016 Apr 5;86(16 Supplement):P4-173.
  • Dupuy S.L, Tauhid S, Hurwitz S, Chu R, Yousuf F, Bakshi R. (September, 2016). The effect of dimethyl fumarate on cerebral gray matter atrophy in multiple sclerosis. Poster presented at: 32nd Congress of the European Committee For Treatment And Research In Multiple Sclerosis; London, GBR.

Acknowledgements

  • Papinutto N, Bakshi R, Bischof A, Calabresi PA, Caverzasi E, Constable RT, et al. Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T1‐weighted brain MRI acquisitions. Magn Reson Med. 2017 Jun 15. PMID: 28617996.

No